Any grade (dose level 1): Thrombocytopenia (62%), Increased ALT (46%), hypertension (23%), fatigue (23%), anemia (23%)DLT: Observed in 10 of 51 (20%) patients overall: neutropenia (10%), thrombocytopenia (10%), nausea (2%), increased ALT (2%). This evidence concerns the gene GPT and anemia.